Browsing by Keyword : Pyrazines
Showing results 1 to 10 of 10
Pub Year | | Title | AJOU Author(s) |
2013 | | Antibody depletion by bortezomib through blocking of antigen presentation. | 박세진 |
2012 | | Bortezomib-resistant nuclear factor κB expression in stem-like cells in mantle cell lymphoma | 정현주 |
2012 | | Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma via manipulation of tissue transglutaminase activities | 정현주 |
2014 | | Changes in osteoblastic activity in patient who received bortezomib as second line treatment for plasma cell myeloma: a prospective multicenter study | 박준성 |
2011 | | Effect of sitagliptin plus metformin on β-cell function, islet integrity and islet gene expression in Zucker diabetic fatty rats. | 강엽, 김대중, 김혜진, 이관우, 한승진 |
2014 | | Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors. | 박준성, 정성현 |
2017 | | Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia | 박준성 |
2012 | | Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial | 박준성 |
2012 | | Simultaneous mitochondrial Ca(2+) overload and proteasomal inhibition are responsible for the induction of paraptosis in malignant breast cancer cells | 최경숙 |
2012 | | Synergistic anticancer effects of arsenic trioxide with bortezomib in mantle cell lymphoma | 정현주 |
1